Silo pharma's spu-21 peptide shows positive results against rheumatoid arthritis

Human tissue study assessed spu-21's efficiency, optimization, and binding affinity englewood cliffs, nj, oct. 16, 2023 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“the company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive data from a preclinical study investigating the binding affinity and optimization of spu-21 liposomal joint homing peptide in human synovial tissue surrounding joints and tendons. spu-21 selectively targets inflamed synovial tissue to inhibit the progression of rheumatoid arthritis (ra).
SILO Ratings Summary
SILO Quant Ranking